HomeABVX • EPA
add
Abivax SA
Previous close
€14.74
Day range
€14.58 - €14.90
Year range
€7.89 - €19.70
Market cap
922.61M EUR
Avg Volume
28.88K
P/E ratio
-
Dividend yield
-
Primary exchange
EPA
In the news
Financials
Income Statement
Revenue
Net income
| (EUR) | Dec 2023info | Y/Y change |
|---|---|---|
Revenue | 1.12M | -0.13% |
Operating expense | 46.21M | 140.46% |
Net income | -47.89M | -142.15% |
Net profit margin | -4.27K | -142.47% |
Earnings per share | — | — |
EBITDA | -45.02M | -149.12% |
Effective tax rate | — | — |
Balance Sheet
Total assets
Total liabilities
| (EUR) | Dec 2023info | Y/Y change |
|---|---|---|
Cash and short-term investments | 260.99M | 868.43% |
Total assets | 327.06M | 332.94% |
Total liabilities | 131.05M | 91.72% |
Total equity | 196.01M | — |
Shares outstanding | 62.92M | — |
Price to book | 4.72 | — |
Return on assets | -34.46% | — |
Return on capital | -41.68% | — |
Cash Flow
Net change in cash
| (EUR) | Dec 2023info | Y/Y change |
|---|---|---|
Net income | -47.89M | -142.15% |
Cash from operations | -34.77M | -137.94% |
Cash from investing | -3.19M | 29.65% |
Cash from financing | 109.27M | 465.57% |
Net change in cash | 68.78M | 39,429.02% |
Free cash flow | -25.39M | -101.77% |
About
Abivax SA is a clinical stage biotechnology company focused on developing innovative treatments that harness the body’s natural regulatory mechanisms to modulate the immune response in patients with chronic inflammatory diseases.
Abivax has one program in clinical development with its lead drug candidate, obefazimod, to treat ulcerative colitis. Another program in Crohn’s disease is also in preparation and other potential inflammatory indications are being evaluated.
The company’s headquarters are based in Paris, France with a US office in Waltham, MA. Abivax’s R&D work is conducted at its research center based in Montpellier, France. Wikipedia
Founded
Dec 4, 2013
Website
Employees
61
